RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results On November 6, 2025, RBC Capital raised its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) from $41 to $45, while maintaining an “Outperform” rating. The investment firm's bullish stance stemmed from clear visibility toward profitability, seen through its increased cash position of $888 million, thanks to financing deals, including $55 million from DRI royalty financing, a $70 million upfront Japan licensing agreement, a $289 million follow-on offering, and access to a $300 million credit facility. Furthermore, Viridian Therapeutics, Inc. (NASDAQ:VRDN) has completed key patient enrollments in its late-stage clinical studies. Readouts for active and chronic Thyroid Eye Disease (TED) are expected in Q1 and Q2 2026, respectively, driving the investment firm's bullish stance. Meanwhile, Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported Q3 2025 results on the previous day. The company c
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- VRDN's page on the SEC website